This technology identifies iron and polyunsaturated fatty acids as dietary factors that suppress tumors via ferroptosis.
Diffuse Large B Cell Lymphoma (DLBCL) is a severe and aggressive form of non-Hodgkin’s lymphoma. The current standard treatment for DLBCL is a combination of chemotherapy drugs, but the application is limited by fitness risks. Even if patients see initial success after chemotherapies, many of them experience relapse and have poor prognoses and limited treatment options. Although CAR T-cell therapies have shown some positive responses, they generate high costs and carry undesirable side effects.
This technology identifies iron and phospholipids with polyunsaturated fatty acyl (PUFA) as dietary factors that suppress Diffuse Large B Cell Lymphoma (DLBCL) via ferroptosis. Ferroptosis is an iron-regulated form of cell death induced by oxidation of PUFA. This technology regulates ferroptosis through dietary modulations to suppress tumor growth and reduce tumor burdens.
This technology has been validated with mouse models.
Patent Pending
IR CU24111
Licensing Contact: Joan Martinez
